Gastric inhibitory polypeptide (GIP) fits a LUCAS-FIBONACCI-midpoint with about 96.4% and thus corroborates Geier's equations and equilibrium concept; Tirzepatide fits with 87% to F9 and the same LUCAS-FIBONACCI-number-midpoint with about 96.3% - A first look by Stefan Geier et al.
Gastric inhibitory polypeptide (GIP) fits a LUCAS-FIBONACCI-number-midpoint with about 96.4% and thus corroborates Geier's equations and equilibrium concept; Tirzepatide fits with 87% to F9 and the same LUCAS-FIBONACCI-number-midpoint with about 96.3% - A first look by Stefan Geier et al. Gastric inhibitory polypeptide (GIP), also known as glucose-dependent insulinotropic polypeptide, is an inhibiting hormone of the secretin family of hormones . While it is a weak inhibitor of gastric acid secretion, its main role, being an incretin , is to stimulate insulin secretion. GIP, along with glucagon-like peptide-1 (GLP-1), belongs to a class of molecules referred to as incretins , which stimulate insulin release on oral food intake. Tirzepatide is an analog of the human GIP hormone with a C20 fatty diacid portion attached, that has been approved for treatment of diabetes in the US in May 2022. The legth of the GIP peptide is 42 amino acids*. We looked for the nearest FIB...